Developing and shedding inhibitions: how MHC class II molecules reach maturity

R Busch; E D Mellins

Developing and shedding inhibitions: how MHC class II molecules reach maturity

R Busch, E D Mellins

Research output: Contribution to journal › Article › peer-review

Abstract

Over the past year, several important advances have been made in understanding the mechanisms by which class II MHC glycoproteins acquire endosomal peptides inside antigen-presenting cells. Recent progress in the study of class II antigen presentation includes the identification of ligands from which invariant chain protects class II molecules in pre-endosomal compartments, an improved understanding of how invariant chain inhibits antigenic peptide binding, and the appreciation that HLA-DM (a factor important for antigen presentation in vivo) can act as a catalyst for peptide exchange.

Original language	English
Pages (from-to)	51-8
Number of pages	8
Journal	Current opinion in immunology
Volume	8
Issue number	1
Publication status	Published - Feb 1996

Keywords

Antigen Presentation
Antigens, Differentiation, B-Lymphocyte
Binding Sites
Endosomes
HLA-D Antigens
Histocompatibility Antigens Class II
Ligands
Models, Immunological
Protein Binding

Cite this

@article{0134cde4a98d4b2284bee4737ebb2f51,

title = "Developing and shedding inhibitions: how MHC class II molecules reach maturity",

abstract = "Over the past year, several important advances have been made in understanding the mechanisms by which class II MHC glycoproteins acquire endosomal peptides inside antigen-presenting cells. Recent progress in the study of class II antigen presentation includes the identification of ligands from which invariant chain protects class II molecules in pre-endosomal compartments, an improved understanding of how invariant chain inhibits antigenic peptide binding, and the appreciation that HLA-DM (a factor important for antigen presentation in vivo) can act as a catalyst for peptide exchange.",

keywords = "Antigen Presentation, Antigens, Differentiation, B-Lymphocyte, Binding Sites, Endosomes, HLA-D Antigens, Histocompatibility Antigens Class II, Ligands, Models, Immunological, Protein Binding",

author = "R Busch and Mellins, {E D}",

year = "1996",

month = feb,

language = "English",

volume = "8",

pages = "51--8",

journal = "Current opinion in immunology",

issn = "0952-7915",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Developing and shedding inhibitions

T2 - how MHC class II molecules reach maturity

AU - Busch, R

AU - Mellins, E D

PY - 1996/2

Y1 - 1996/2

N2 - Over the past year, several important advances have been made in understanding the mechanisms by which class II MHC glycoproteins acquire endosomal peptides inside antigen-presenting cells. Recent progress in the study of class II antigen presentation includes the identification of ligands from which invariant chain protects class II molecules in pre-endosomal compartments, an improved understanding of how invariant chain inhibits antigenic peptide binding, and the appreciation that HLA-DM (a factor important for antigen presentation in vivo) can act as a catalyst for peptide exchange.

AB - Over the past year, several important advances have been made in understanding the mechanisms by which class II MHC glycoproteins acquire endosomal peptides inside antigen-presenting cells. Recent progress in the study of class II antigen presentation includes the identification of ligands from which invariant chain protects class II molecules in pre-endosomal compartments, an improved understanding of how invariant chain inhibits antigenic peptide binding, and the appreciation that HLA-DM (a factor important for antigen presentation in vivo) can act as a catalyst for peptide exchange.

KW - Antigen Presentation

KW - Antigens, Differentiation, B-Lymphocyte

KW - Binding Sites

KW - Endosomes

KW - HLA-D Antigens

KW - Histocompatibility Antigens Class II

KW - Ligands

KW - Models, Immunological

KW - Protein Binding

M3 - Article

C2 - 8729446

SN - 0952-7915

VL - 8

SP - 51

EP - 58

JO - Current opinion in immunology

JF - Current opinion in immunology

IS - 1

ER -